{"id":"W2601316275","doi":"10.1200/jco.2013.31.15_suppl.3030","title":"Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Immunovaccine (Canada); University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; ELISPOT; Immunogenicity; Immune system; Cyclophosphamide; Ovarian cancer; Adverse effect; Internal medicine; Cohort; Cancer; Survivin; Immunology; Oncology; Chemotherapy; Gastroenterology; CD8","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009110468,0.0006592872,0.001054137,0.0002144988,0.0002279918,0.0004310185,0.0003643538,0.0006014127,0.001665997],"category_scores_gemma":[0.0005539712,0.0002875649,0.0007536759,0.0002479077,0.0004986664,0.0003671649,0.0001837131,0.001444329,0.0003690576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004401332,"about_ca_system_score_gemma":0.0007770983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006001322,"about_ca_topic_score_gemma":0.0007467395,"domain_scores_codex":[0.9997481,0.0001177615,0.00001266212,0.00003860611,0.00002788783,0.00005510643],"domain_scores_gemma":[0.9994425,0.0001304227,0.000113548,0.00006300868,0.00003352178,0.0002170486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5327584,0.1303104,0.02278911,0.0008616921,0.00147744,0.0003685104,0.0003987123,0.002871512,0.1093664,0.0001591304,0.002658819,0.19598],"study_design_scores_gemma":[0.09235469,0.8655409,0.0336859,0.00001981514,0.0003366362,0.0002875993,0.00004131034,0.0007536015,0.005458369,0.00006683962,0.001442234,0.00001209112],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979691,0.0006975512,0.0001536305,0.00007536844,0.00002018714,0.0004273019,0.0001956332,0.00001857114,0.0004425214],"genre_scores_gemma":[0.9972077,0.0006817484,0.0003276382,0.0002058095,0.00006360036,0.0004086706,0.0005568526,0.0000110813,0.0005369626],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001665997,"threshold_uncertainty_score":0.005573332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04492855343445169,"score_gpt":0.4162326775029944,"score_spread":0.3713041240685427,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}